The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to ...

LILLE, France & PARIS--(BUSINESS WIRE)--Regulatory News: Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research ...

ProMIS Neurosciences Inc., a clinical-stage biotechnology firm, announced its plan to present preclinical data on novel computationally-derived vaccines targeting neurodegenerative diseases at the ...

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ...

From biomarker discovery to safety pharmacology, CD BioSciences preclinical development services for anti-aging drug research span the full range. These services, by combining advanced technology and ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...